Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03117998 |
Recruitment Status :
Recruiting
First Posted : April 18, 2017
Last Update Posted : October 14, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety, and pharmacodynamics (PD) of multiple doses of REMD-477 in subjects who have Type 1 diabetes and are currently receiving insulin treatment. This study will determine whether REMD-477 can decrease daily insulin requirements and improve glycemic control after 12 weeks of treatment in subjects diagnosed with Type 1 diabetes with fasting C-peptide < 0.7 ng/mL at Screening.
The study will be conducted at multiple sites in the United States. Approximately 150 subjects with type 1 diabetes on stable doses of insulin will be randomized in a 1:1:1 fashion into one of three treatment groups.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type1 Diabetes Mellitus | Biological: REMD-477 Biological: Placebo Comparator | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Multiple Doses of REMD-477 in Subjects With Type 1 Diabetes Mellitus |
Actual Study Start Date : | September 19, 2017 |
Estimated Primary Completion Date : | January 30, 2021 |
Estimated Study Completion Date : | April 30, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: REMD-477 Treatment A
Administered as a repeated subcutaneous (SC) doses in subjects with Type 1 Diabetes
|
Biological: REMD-477
Administered as repeated SC doses in subjects with Type 1 Diabetes |
Experimental: REMD-477 Treatment B
Administered as a repeated SC doses in subjects with Type 1 Diabetes
|
Biological: REMD-477
Administered as repeated SC doses in subjects with Type 1 Diabetes |
Placebo Comparator: Matching placebo
Administered as a repeated SC doses in subjects with Type 1 Diabetes
|
Biological: Placebo Comparator
Administered as a repeated SC doses in subjects with Type 1 Diabetes |
- Daily Insulin Use [ Time Frame: 12 weeks ]Change in daily insulin use from baseline at Week 12
- Glucose after Mixed Meal Tolerance Test (MMTT) [ Time Frame: 13 weeks ]Change from baseline at Week 13 in fasting glucose and glucose area under the curve (AUC) after the Mixed Meal Tolerance Test (MMTT) after repeated doses of REMD-477.
- Continuous Glucose Monitoring (CGM) [ Time Frame: 12 weeks ]Change from baseline at Week 12 in average daily 24-h blood glucose as assessed by CGM after repeated doses of REMD-477.
- Seven-Point Glucose Profile [ Time Frame: 12 weeks ]Change from baseline at Week 12 in the average daily 24-h blood glucose concentration as assessed by seven-point glucose profile after repeated doses of REMD-477.
- Product of the ratio of average glucose and insulin [ Time Frame: 12 weeks ]The product of the ratio of average glucose (Week 12/Baseline) and ratio of average insulin use (Week 12/Baseline).
- Adverse Events [ Time Frame: 24 weeks ]Number of treatment emergent adverse events per subject, including clinically relevant changes in medical history, physical examination, laboratory safety values, and ECGs
- Hypoglycemic Events [ Time Frame: 12 weeks ]Incidence of hypoglycemic events, after repeated doses of REMD-477
- HbA1c at Week 13 [ Time Frame: 13 weeks ]Change from baseline at Week 13 in HbA1c, after repeated doses of REMD-477.
- HbA1c Reduction of ≥ 0.4% [ Time Frame: 12 weeks ]Proportion of subjects who achieve HbA1c reduction of ≥ 0.4%, after repeated doses of REMD-477
- C-peptide after MMTT and Arginine Challenge [ Time Frame: 13 weeks ]Change from baseline at Week 13 in fasting C-peptide and C-peptide AUC after MMTT and arginine challenge, after repeated doses of REMD-477.
- Glucagon after MMTT [ Time Frame: 13 weeks ]Change from baseline at Week 13 in peripheral levels of fasting glucagon and glucagon AUC after MMTT challenge, after repeated doses of REMD-477.
- GLP-1 after MMTT [ Time Frame: 13 weeks ]Change from baseline at Week 13 in peripheral levels of active and total glucagon-like peptide 1 (GLP-1), and GLP-1 (active and total) AUC after MMTT challenge, after repeated doses of REMD-477.
- Immunogenicity [ Time Frame: 24 weeks ]Incidence of REMD-477 antibody formation.
- Peak Serum Concentration [ Time Frame: 24 weeks ]Maximum observed concentration (Cmax) after repeated doses of REMD-477.
- Area under the serum concentration [ Time Frame: 24 weeks ]Area under the curve (AUC) serum-concentration after repeated doses of REMD-477.
- Half-life of REMD-477 [ Time Frame: 24 weeks ]Half-life (t1/2) after repeated doses of REMD-477.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men and women between the ages of 18 and 65 years old, inclusive, at the time of screening;
- Females of non-child bearing potential must be ≥1 year post-menopausal (confirmed by a serum follicle-stimulating hormone (FSH) levels ≥ 40 IU/mL) or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception;
- Male subjects must be willing to use clinically acceptable method of contraception during the entire study;
- Body mass index between 18.5 and 32 kg/m2, inclusive, at screening;
- Diagnosed with Type 1 diabetes, based on clinical history or as defined by the current American Diabetes Association (ADA) criteria;
- HbA1c > 7% and < 10 % at screening;
- Fasting C-peptide < 0.7 ng/mL;
- Treatment with a stable insulin regimen for at least 8 weeks before screening with multiple daily insulin (MDI) injections or continue subcutaneous insulin infusion (CSII)
- Willing to use continuous CGM system (e.g. DexCom) throughout the study;
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 1.5x upper limit of normal (ULN) at screening;
- Able to provide written informed consent approved by an Institutional Review Board (IRB).
Exclusion Criteria:
- History or evidence of clinically-significant disorder or condition that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion;
- Significant organ system dysfunction (e.g., clinically significant pulmonary or cardiovascular disease, anemia [Hemoglobin < 10.0 g/dL], known hemoglobinopathies, and renal dysfunction [eGFR < 60 ml/min]);
- Any severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or medical facility in the past 6 months;
- Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident ≤12 weeks before screening;
- History of New York Heart Association Functional Classification III-IV cardiac disease;
- Current or recent (within 1 month of screening) use of diabetes medications other than insulin - subjects on an SGLT2 inhibitor should be discontinue the SGLT2 inhibitor during the Screening Period, at least 2 weeks prior to the start of the Lead-in Period;
- Use of steroids and/or other prescribed or over-the-counter medications that are known to affect the outcome measures in this study or known to influence glucose metabolism;
- Smokes > 10 cigarettes/day, and/or is unwilling to abstain from smoking during admission periods;
- Known sensitivity to mammalian-derived drug preparations, recombinant protein-based drugs or to humanized or human antibodies;
- History of illicit drug use or alcohol abuse within the last 6 months or a positive drug urine test result at screening;
- History of pancreatitis, pancreatic neuroendocrine tumors or multiple endocrine neoplasia (MEN) or family history of MEN;
- History of pheochromocytoma, or family history of familial pheochromocytoma;
- Known or suspected susceptibility to infectious disease (e.g. taking immunosuppressive agents or has a documented inherited or acquired immunodeficiency);
- Known history of positive for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C antibodies (HepC Ab);
- Participation in an investigational drug or device trial within 30 days of screening or within 5 times the half-life of the investigational agent in the other clinical study, if known, whichever period is longer;
- Blood donor or blood loss > 500 mL within 30 days of Day 1;
- Women who are pregnant or lactating/breastfeeding;
- Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits;
- Any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent
Other inclusion and exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03117998
Contact: Dung "Zung" Thai, MD | 805-987-0600 | zungthai@remdbio.com |
United States, California | |
AMCR Institute | Recruiting |
Escondido, California, United States, 92025 | |
Contact: Timonthy S Bailey, MD 760-466-1523 | |
Marin Endocrine Care & Research | Recruiting |
Greenbrae, California, United States, 94904 | |
Contact: Mickie Cheng, MD 415-461-1780 | |
Altman Clinical and Translational Research Institute | Recruiting |
San Diego, California, United States, 92037 | |
Contact: Todd May 858-657-7039 tmay@ucsd.edu | |
Diablo Clinical Research | Recruiting |
Walnut Creek, California, United States, 94598 | |
Contact: Caitlin Sheets 925-930-7267 csheets@Diabloclinical.com | |
Contact: Mark Christiansen, MD | |
United States, Colorado | |
University of Colorado, Denver/Barbara Davis Center for Diabetes | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Halis Kaan Akturk, MD 303-724-6761 halis.akturk@ucdenver.edu | |
United States, Georgia | |
Atlanta Diabetes Assoicates | Recruiting |
Atlanta, Georgia, United States, 30318 | |
Contact: Bruce W Bode, MD 404-355-4393 | |
United States, Missouri | |
Washington University School of Medicine | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
Contact: Karen Flavin 314-747-8592 flavinkarens@wustl.edu | |
United States, Texas | |
Texas Diabetes & Endocrinology | Recruiting |
Austin, Texas, United States, 78749 | |
Contact: Jean Chen, MD 512-334-3505 | |
Dallas Diabetes Research Center | Recruiting |
Dallas, Texas, United States, 75230 | |
Contact: Julio Rosenstock, MD 972-566-7799 juliorosenstock@dallasdiabetes.com | |
Clinical Trials of Texas | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: Douglas S Denham, DO 210-949-0122 | |
United States, Washington | |
Rainer Clinical Research Center | Recruiting |
Renton, Washington, United States, 98057 | |
Contact: Leslie Klaff, MD 425-251-1720 ljklaff@rainier-research.com |
Responsible Party: | REMD Biotherapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT03117998 |
Other Study ID Numbers: |
R477-202 |
First Posted: | April 18, 2017 Key Record Dates |
Last Update Posted: | October 14, 2020 |
Last Verified: | October 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Autoimmune Diseases Immune System Diseases REMD-477 Hypoglycemic Agents Physiological Effects of Drugs |